{"entity":{"id":"nct05853575","kind":"trial","name":"Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)","aka":["KRYSTAL 21"],"tldr":"A phase 2 trial of Adagrasib in metastatic cancer, run by Mirati Therapeutics Inc., active and no longer recruiting.","summary":"Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) is a phase 2 interventional study registered as NCT05853575 by Mirati Therapeutics Inc., with 200 participants planned, started 2024-02-01 and due to reach its primary completion in 2026-10-30. Interventions recorded: Adagrasib. Conditions listed: Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05853575","url":"https://clinicaltrials.gov/study/NCT05853575"}],"tags":["ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["kras-inhibitors"],"targets":[],"drugs":["adagrasib"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05853575","phase":"2","setting":"A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation","sponsor":"Mirati Therapeutics Inc.","participation":[{"nct":"NCT05853575","source":"https://clinicaltrials.gov/study/NCT05853575","fetchedAt":"2026-10-07T16:53:58.081Z","studySha256":"24763bbb314a916004f3532887c13f91fd946b8e02cabc86616a4e06aa6cc64d","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-08-14","leadSponsor":"Mirati Therapeutics Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":200,"enrolmentType":"ESTIMATED","siteCount":98,"recruitingSiteCount":0,"countries":["Brazil","Croatia","France","Greece","Israel","Italy","Japan","Mexico","Netherlands","Poland","Romania","Serbia","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United States"]}],"started":"2024-02-01","startedType":"actual","enrolled":200,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05853575/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"}],"drug":[{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}